[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2725726B1 - Vecteurs viraux et utilisation en therapie genique - Google Patents

Vecteurs viraux et utilisation en therapie genique

Info

Publication number
FR2725726B1
FR2725726B1 FR9412346A FR9412346A FR2725726B1 FR 2725726 B1 FR2725726 B1 FR 2725726B1 FR 9412346 A FR9412346 A FR 9412346A FR 9412346 A FR9412346 A FR 9412346A FR 2725726 B1 FR2725726 B1 FR 2725726B1
Authority
FR
France
Prior art keywords
gene therapy
viral vectors
viral
vectors
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9412346A
Other languages
English (en)
Other versions
FR2725726A1 (fr
Inventor
Michel Perricaudet
Martin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9412346A priority Critical patent/FR2725726B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US08/817,494 priority patent/US6669942B2/en
Priority to JP51298396A priority patent/JP3816952B2/ja
Priority to PCT/FR1995/001326 priority patent/WO1996012030A1/fr
Priority to AU36584/95A priority patent/AU712243B2/en
Priority to EP95934200A priority patent/EP0787198A1/fr
Priority to CA002201399A priority patent/CA2201399A1/fr
Priority to IL11558495A priority patent/IL115584A/xx
Priority to ZA958686A priority patent/ZA958686B/xx
Publication of FR2725726A1 publication Critical patent/FR2725726A1/fr
Application granted granted Critical
Publication of FR2725726B1 publication Critical patent/FR2725726B1/fr
Priority to NO971590A priority patent/NO971590D0/no
Priority to FI971613A priority patent/FI971613A0/fi
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9412346A 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique Expired - Fee Related FR2725726B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique
JP51298396A JP3816952B2 (ja) 1994-10-17 1995-10-11 治療遺伝子と免疫保護遺伝子とを含む欠陥アデノウイルス
PCT/FR1995/001326 WO1996012030A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
AU36584/95A AU712243B2 (en) 1994-10-17 1995-10-11 Defective adenoviruses including a therapeutic gene and an immunoprotective gene
EP95934200A EP0787198A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
CA002201399A CA2201399A1 (fr) 1994-10-17 1995-10-11 Adenovirus defectifs comprenant un gene therapeutique et un gene immunoprotecteur
US08/817,494 US6669942B2 (en) 1994-10-17 1995-10-11 Defective adenoviruses including a therapeutic gene and an immunoprotectove gene
IL11558495A IL115584A (en) 1994-10-17 1995-10-12 Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein
ZA958686A ZA958686B (en) 1994-10-17 1995-10-13 Viral vectors and use in gene therapy
NO971590A NO971590D0 (no) 1994-10-17 1997-04-07 Defektive adenovirus omfattende et terapeutisk gen og et immunobeskyttende gen
FI971613A FI971613A0 (fi) 1994-10-17 1997-04-16 Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
FR2725726A1 FR2725726A1 (fr) 1996-04-19
FR2725726B1 true FR2725726B1 (fr) 1997-01-03

Family

ID=9467911

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9412346A Expired - Fee Related FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Country Status (11)

Country Link
US (1) US6669942B2 (fr)
EP (1) EP0787198A1 (fr)
JP (1) JP3816952B2 (fr)
AU (1) AU712243B2 (fr)
CA (1) CA2201399A1 (fr)
FI (1) FI971613A0 (fr)
FR (1) FR2725726B1 (fr)
IL (1) IL115584A (fr)
NO (1) NO971590D0 (fr)
WO (1) WO1996012030A1 (fr)
ZA (1) ZA958686B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079830C (zh) * 1993-04-20 2002-02-27 索利斯治疗学公司 对受胞内传染原感染的个体进行治疗的方法和物质
AU697022B2 (en) * 1995-02-24 1998-09-24 Trustees Of The University Of Pennsylvania, The Methods and compositions for administering gene therapy vectors
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
WO1998000166A1 (fr) * 1996-07-03 1998-01-08 Merial, Inc. ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
US6083716A (en) * 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP1025242A1 (fr) 1997-10-30 2000-08-09 Cornell Research Foundation, Inc. Procede inhibant la reponse immunitaire a un vecteur recombine
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
JP2002541815A (ja) * 1999-04-09 2002-12-10 シェーリング−プラウ・リミテッド ウシアデノウイルス１型から誘導された組換えアデノウイルスおよび変異アデノウイルス
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
ATE519855T1 (de) * 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US7468181B2 (en) * 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
EP1157999A1 (fr) * 2000-05-24 2001-11-28 Introgene B.V. Méthodes et moyens pour améliorer la transplantation de la peau en utilisant des vecteurs d'apport de genes munis d'un tropisme pour des fibroblastes primaires ainsi que d'autres utilisations de celles-ci
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1203819A3 (fr) 2000-10-06 2002-08-07 Transgene S.A. Vecteurs anti-inflammatoires
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
ATE511401T1 (de) 2004-08-12 2011-06-15 Cedars Sinai Medical Center Kombinierte gentherapie zur behandlung makroskopischer glioma
CA2597647A1 (fr) 2005-02-11 2007-08-02 University Of Southern California Procedes d'expression de proteines avec des ponts disulfure
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
US8883493B2 (en) 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20100273220A1 (en) 2009-04-22 2010-10-28 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
US10837020B2 (en) * 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
WO2012125791A2 (fr) * 2011-03-17 2012-09-20 Xiaoliu Zhang Incorporation du gène b18r pour stimuler l'effet antitumoral d'une virothérapie
US8445781B1 (en) 2011-11-15 2013-05-21 Nova D. Chasser Electrical receptacle cover having safety bracket for use with fragrance dispenser
CA3036293A1 (fr) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Nouveaux promoteurs
TWI817933B (zh) 2016-09-20 2023-10-11 德商百靈佳殷格翰維美迪加股份有限公司 新穎ehv插入位點orf70
CN109715219B (zh) 2016-09-20 2024-03-01 勃林格殷格翰动物保健有限公司 犬腺病毒载体
EA201990717A1 (ru) 2016-09-20 2019-10-31 Новая вакцина против гриппа свиней
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
EP4221738A1 (fr) 2020-09-30 2023-08-09 Alma Bio Therapeutics Thérapie par acide nucléique pour la modulation différentielle de la microflore hôte

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322286T1 (de) * 1991-10-04 2006-04-15 Whitehead Biomedical Inst Regulierung der systemischen immunantworten mittels zytokinen und antigenen
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (fr) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Therapie de tumeurs
CA2145641C (fr) * 1992-12-03 2008-05-27 Richard J. Gregory Vecteurs pseudo-adenoviraux
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
JPH10507079A (ja) 1998-07-14
NO971590L (no) 1997-04-07
NO971590D0 (no) 1997-04-07
CA2201399A1 (fr) 1996-04-25
ZA958686B (en) 1996-05-22
EP0787198A1 (fr) 1997-08-06
IL115584A (en) 2005-11-20
FI971613A (fi) 1997-04-16
US20020006395A1 (en) 2002-01-17
JP3816952B2 (ja) 2006-08-30
AU3658495A (en) 1996-05-06
FI971613A0 (fi) 1997-04-16
FR2725726A1 (fr) 1996-04-19
AU712243B2 (en) 1999-11-04
US6669942B2 (en) 2003-12-30
IL115584A0 (en) 1996-01-19
WO1996012030A1 (fr) 1996-04-25

Similar Documents

Publication Publication Date Title
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
ZA949104B (en) Recombinant viruses and their use in gene therapy
ZA951803B (en) Recombinant viruses their preparation and their therapeutic use
PT797431E (pt) Formulacoes de peptidios e proteinas em aerossol
NO943344D0 (no) MN-gen og -protein
DK0941056T3 (da) Sphingomyelinasepræparater samt anvendelse deraf
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
DE69526002D1 (de) Aufladegerät und Aufladevorrichtung
IL111682A0 (en) Recombinant viruses and their use in gene therapy
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
IL117466A0 (en) Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy
KR950700316A (ko) 재조합 지베렐린 디엔에이(dna) 및 이들의 사용 방법(recombinant gibberellin dna and uses thereof)
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
IL114688A0 (en) Vectors and transformed host cells
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
KR960010685A (ko) 펩티드 및 그 용도
ZA952244B (en) Recombinant viruses their preparation and their use in gene therapy
NO990303D0 (no) Lipidbindende proteiner og deres terapeutiske og diagnostiske anvendelse
FR2766049B1 (fr) Cyclotron compact et son utilisation en proton-therapie
ZA952286B (en) Recombinant viruses their preparation and their use in gene therapy
ZA952243B (en) Recombinant viruses their preparation and their use in gene therapy
FR2726575B1 (fr) Virus recombinants, preparation et utilisation en therapie genique
NO954530L (no) Aryloksycykloalkenyl- og aryloksyimino-cykloalkenylhydroksyurinstoffer

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20080630